Relationship between urinary and serum growth hormone and pubertal status

E C Crowne, W H B Wallace, S M Shalet, G M Addison, D A Price

Abstract

Urinary growth hormone (uGH) excretion and serum growth hormone concentrations have been compared in three groups of children. Group 1 consisted of 21 children who had had cranial irradiation as part of their treatment for acute lymphoblastic leukaemia; group 2, 18 normal children; and group 3, 12 boys with constitutional delay in growth and puberty who were in early puberty. Children in groups 1 and 2 each had a 24 hour serum growth hormone profile (sampling every 20 minutes) and concurrent urine collection. The 12 boys in group 3 had a total of 21 profiles (sampling every 15 minutes for 12 hours) and concurrent urine collections.

In the prepubertal children (n=17), in both groups 1 and 2, there was a significant correlation between mean serum growth hormone and total uGHng/g creatinine. There were also significant correlations between total uGHng/g creatinine and both peak serum growth hormone and mean amplitude of the pulses in the growth hormone profile. In the pubertal children (n=22), in groups 1 and 2, whether combined or in separate groups, there was no significant correlation between total uGHng/g creatinine and mean serum growth hormone, peak serum growth hormone, or mean amplitude of the pulses in the growth hormone profile. In group 3 there were significant correlations between total uGHng/g creatinine and both the mean serum growth hormone and mean amplitude of the pulses in the profile. Therefore uGH estimations appear to correlate well with serum growth hormone profiles in children who are pre-pubertal or in early puberty, but not in those further advanced in pubertal development. These results may reflect a variation in the renal handling of growth hormone during pubertal development. uGH estimation may be an unreliable screening investigation for growth hormone insufficiency in mid to late puberty.

The diversity of tests of growth hormone secretion in clinical use indicates the absence of an ideal test of growth hormone secretion. In clinical practice pharmacological stimulation tests such as insulin, arginine, or glucagon with an arbitrarily assigned ‘normal’ cut off value have been used to identify growth hormone deficient children. These tests do not provide information about physiological growth hormone secretion, and 24 hour serum growth hormone profiles for the assessment of physiological growth hormone secretion have obvious drawbacks in terms of invasiveness and cost. Hence the interest in estimation of urinary excretion of growth hormone as a non-invasive, easily performed test. Growth hormone assays have now attained the sensitivity required to detect the minute amounts of the hormone excreted in the urine,1-3 and their use is being advocated as a means of screening for growth hormone deficiency.4 Abnormalities in growth hormone secretion in children and adults who have had cranial irradiation as part of their treatment for malignancies are well established.5-8 Abnormalities ranged from growth hormone deficiency defined by classical criteria,9 neurosecretory dysfunction with normal growth hormone responses to pharmacological tests but subnormal physiological growth hormone secretion,7 and a failure of the puberty associated rise in spontaneous growth hormone secretion.6 Children who have had cranial irradiation are therefore a particular group in whom screening tests of growth hormone need to be reliable enough to detect subtle changes in physiological growth hormone secretion.

Other categories of children frequently seen in a paediatric growth clinic include those with constitutional delay in growth and puberty (CDGP) or familial short stature. A simple, easily performed non-invasive means of assessing growth hormone secretion in such individuals would be very helpful.

In this study we have therefore compared urinary growth hormone (uGH) estimations and serum growth hormone profiles in three groups of children: normal children, children who have had low dose cranial irradiation as part of their treatment for acute lymphoblastic leukaemia (ALL), and boys with CDGP.

Patients and methods

GROUP 1: AFTER CRANIAL IRRADIATION

Twenty one children, aged 6-9-18-2 years (nine girls, 12 boys) who had received prophylactic cranial irradiation during treatment for ALL were studied. Nineteen received 18 Gy in 10 fractions over 14 days and two received 24 Gy in 10 fractions over 14 days. All 21 had received chemotherapy according to standard UK protocols, were in first remission, and a mean (SD) 6-4 (1-9) years from radiotherapy.

GROUP 2: NORMAL CHILDREN

Eighteen normal children, aged 3-8-18-9 years (six girls, 12 boys) were studied. Ten were
normal siblings of group 1 and eight were children under investigation for genetic short stature (height velocity normal and normal growth hormone response to pharmacological stimulation tests but with a mid-parental height less than the 10th centile and a standing height more than 2 SD below the mean).

GROUP 3: CDGP
Twelve boys under investigation for CDGP were studied. They had a total of 21 profiles with concurrent urine collections before and after treatment with either low dose testosterone, oxandrolone, or placebo. Only six of the profiles were performed while the boys were actively receiving either oxandrolone (n=2) or testosterone (n=4).

The groups were further subdivided by pubertal stage according to the method of Tanner and Whitehouse.† Children in groups 1 and 2 each had a 24 hour growth hormone profile sampling every 20 minutes with concurrent urine collection (0900–0900 hours). Group 3 boys had an overnight 12 hour profile on each occasion (2000–0800 hours), with sampling every 15 minutes and a concurrent urine collection. Details of the children at the time of the profile are shown in table 1.

All the studies were approved by the local ethical committee and informed consent was obtained from the children and their parents.

ASSAYS
Serum growth hormone profiles were assayed in one batch using a standard diagnostic immunoradiometric assay (IRMA) kit (Netria, St Bartholomew’s Hospital, London), and international reference standards. Urine samples were collected in polythene bottles kept at 4°C during the collection. Urine volumes were then measured and aliquots stored at −40°C in 0·1% bovine serum albumin and 0·1% azide solution until assayed, when aliquots were first dialysed against a phosphate buffer for 24 hours at 4°C. Growth hormone concentration was measured by a two step IRMA using 1·5 ml of dialysed urine. The first step consisted of a 24 hour incubation with 100 µl of 125I labelled mouse monoclonal anti-human growth hormone antibody, and the second a 24 hour incubation with 100 µl of sheep polyclonal antigurowth hormone antibody coupled to a solid phase (antibodies obtained from Netria). Both incubations were at 4°C. Sensitivity was 0·8 pg/ml, intra-assay coefficients of variation were 2·0–8·1%, and interassay coefficients of variation 6·6–8·4%.

Urinary creatinine estimations were performed by the standard Jaffe kinetic method.

**Table 1** Age and pubertal stage at the time of profile. Results are mean (SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>Age at study</th>
<th>Pubertal stage</th>
<th>Time since treatment</th>
<th>Age at treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: ALL (after irradiation) Prepubertal (n=7)</td>
<td>9·6 (1·8)</td>
<td>—</td>
<td>6·6 (1·8)</td>
<td>3·8 (2·1)</td>
</tr>
<tr>
<td>Pubertal (n=14)</td>
<td>14·1 (2·0)</td>
<td>—</td>
<td>6·5 (1·7)</td>
<td>7·3 (3·1)</td>
</tr>
<tr>
<td>2: Normal children Prepubertal (n=10)</td>
<td>8·7 (2·4)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Pubertal (n=8)</td>
<td>15·3 (2·6)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>3: CDGP (n=21)</td>
<td>14·5 (0·9)</td>
<td>TV 5–12 ml (n=3), TV 25 ml (n=3), B3–B4 (n=2), B5 (n=6)</td>
<td>6·5 (1·7)</td>
<td>7·3 (3·1)</td>
</tr>
</tbody>
</table>

TV= testicular volume, B= breast stage.

CALCULATIONS AND STATISTICS
Results are expressed as mean (SD). Results of uGH (22 pg/ml=1 μmol/l) are expressed as ng per gram of creatinine to avoid inaccuracies due to incomplete or inaccurate urine collections and to allow comparison with published reports. Growth hormone profiles were analysed using the Pulsar Peak Detection Programme.12 Correlations and regressions were calculated by standard least squares. Differences between groups were analysed using the Mann-Whitney U test. The significance of regression lines was calculated using Student’s unpaired t test, the significance of the difference between regression lines calculated using a method of weighting.13

Results
There were no significant differences in mean peak and total concentrations of serum growth hormone within group 2, that is between the normal siblings and those under investigation for genetic short stature. In group 1, there was no significant difference in time since cranial irradiation between the prepubertal and pubertal children (6·6 (1·8) v 6·5 (1·7) years) but there was a significant difference in age at cranial irradiation between the prepubertal and pubertal children (3·8 (2·1) v 7·5 (3·0) years, p<0·05).

RELATIONSHIP BETWEEN SERUM GROWTH HORMONE PROFILES AND UGH EXCRETION IN PREPUBERTAL CHILDREN (FIG I)
There was a significant correlation between mean serum growth hormone and total uGHng/g

![Figure 1](http://adc.bmj.com/)  
*Figure 1* Relationship between total uGH excretion and mean serum growth hormone concentrations in 17 prepubertal children. Conversion factor for growth hormone: 2 IUL=1 ng/l.
creatinine in the prepubertal children (r=0.82; p=0.001). The relationship was described by the regression equation \( y = 1.48 + 0.15x \) (fig 1). The correlation between these two parameters was also significant in groups 1 and 2 taken separately (r=0.88, p=0.009; r=0.84, p=0.003 respectively), and there was no significant difference in the regression equations between the two groups. There were also significant correlations in the prepubertal children between total uGHng/g creatinine and both peak growth hormone in the growth hormone profile (r=0.86, p<0.001) and mean pulse amplitude in the growth hormone profile (r=0.71, p=0.002).

**RELATIONSHIP BETWEEN SERUM GROWTH HORMONE PROFILE AND uGH EXCRETION IN BOYS WITH CDGP IN EARLY PUBERTY**

There were significant correlations between total uGHng/g creatinine and both mean serum growth hormone (r=0.74, p<0.001) and mean amplitude of the growth hormone pulses in the 12 hour profile (r=0.4, p=0.05) in these boys. There was, however, no significant correlation between the total uGH excreted and the peak growth hormone in the profile (r=0.4, p=0.12).

**RELATIONSHIP BETWEEN SERUM GROWTH HORMONE PROFILES AND uGH EXCRETION IN PUBERTAL CHILDREN (FIG 2)**

The relationship between mean serum growth hormone and total uGHng/g creatinine was not significant in the pubertal children (r=–0.26, p=0.24) as seen in fig 2. The regression equation \( y = 4.84 - 0.03x \) was significantly different to that of the prepubertal group (p<0.001) but not significantly different from zero. The correlation between these two parameters was also not significant in either group 1 or 2 taken separately (r=–0.02, p=1.0; r=–0.4, p=0.22 respectively). Nor was there a significant correlation between these parameters in the boys and girls taken separately (r=–0.2, p=0.60; r=–0.6, p=0.1 respectively). In addition, there were no significant correlations

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Intravenous pyelogram at diagnosis</th>
<th>Nephrotoxic drugs</th>
<th>Renal function*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal</td>
<td>Amikacin</td>
<td>N</td>
</tr>
<tr>
<td>2</td>
<td>Normal</td>
<td>Amikacin</td>
<td>T</td>
</tr>
<tr>
<td>4</td>
<td>Normal</td>
<td>—</td>
<td>N</td>
</tr>
<tr>
<td>6</td>
<td>Normal</td>
<td>Gentamicin</td>
<td>T</td>
</tr>
<tr>
<td>7</td>
<td>Normal</td>
<td>Amikacin</td>
<td>N</td>
</tr>
<tr>
<td>12</td>
<td>Normal</td>
<td>Neutamycin</td>
<td>T</td>
</tr>
<tr>
<td>16</td>
<td>Normal</td>
<td>Neutamycin</td>
<td>T</td>
</tr>
<tr>
<td>3</td>
<td>Normal</td>
<td>Gentamicin, amikacin</td>
<td>T</td>
</tr>
<tr>
<td>5</td>
<td>Normal</td>
<td>Amikacin</td>
<td>N</td>
</tr>
<tr>
<td>8</td>
<td>Normal</td>
<td>—</td>
<td>N</td>
</tr>
<tr>
<td>9</td>
<td>Normal</td>
<td>Amikacin</td>
<td>N</td>
</tr>
<tr>
<td>10</td>
<td>Not performed</td>
<td>Amikacin</td>
<td>T</td>
</tr>
<tr>
<td>11</td>
<td>Normal</td>
<td>Gentamicin, amikacin</td>
<td>T</td>
</tr>
<tr>
<td>13</td>
<td>Normal</td>
<td>—</td>
<td>N</td>
</tr>
<tr>
<td>14</td>
<td>Normal</td>
<td>Neutamycin, amikacin</td>
<td>T</td>
</tr>
<tr>
<td>15</td>
<td>Leukaemic infiltration</td>
<td>Gentamicin</td>
<td>N</td>
</tr>
<tr>
<td>17</td>
<td>Normal</td>
<td>Amikacin</td>
<td>N</td>
</tr>
<tr>
<td>18</td>
<td>Normal</td>
<td>—</td>
<td>N</td>
</tr>
<tr>
<td>19</td>
<td>Normal</td>
<td>—</td>
<td>N</td>
</tr>
<tr>
<td>20</td>
<td>Leukaemic infiltration</td>
<td>Neutamycin</td>
<td>T</td>
</tr>
<tr>
<td>21</td>
<td>Normal</td>
<td>—</td>
<td>N</td>
</tr>
</tbody>
</table>

*Renal function: N=normal blood urea and creatinine concentration, T=transiently raised concentrations during treatment, subsequently normal.

**Figure 2** Relationship between total uGHng/g creatinine and mean serum growth hormone concentrations in 22 pubertal children. Conversion factor for growth hormone: 1 IU/l = 1 μg/l.

in the pubertal group between total uGHng/g creatinine and either peak growth hormone in the growth hormone profile (r=–0.29, p=0.02) or mean amplitude of the growth hormone pulses in the growth hormone profile (r=–0.34, p=0.02). Expressing uGH excretion as a uGHng/g creatinine ratio or as total uGH (pg) did not alter these results. The six pubertal boys in groups 1 and 2 with testicular volumes less than 12 ml (that is, at a similar pubertal stage to the boys in group 3) did, however, show a significant correlation between total uGHng/g creatinine and both mean serum growth hormone and mean amplitude of the growth hormone pulses (r=–0.74, p=0.09; r=–0.72, p=0.01 respectively) when analysed separately.

**RENALE FUNCTION**

All the children studied had normal plasma urea and creatinine concentrations. In particular the group with ALL had normal renal function after their chemotherapy. Factors during the course of their treatment affecting renal function are shown in table 2.

All the children except one had an intravenous pyelogram at diagnosis. Two showed evidence of leukaemic infiltration. The children all received chemotherapy according to standard protocols and these did not include known nephrotoxic drugs. During their treatment, however, 14 children received antibiotics known to be nephrotoxic for treatment of intercurrent infections while immunosuppressed. Five were in the prepubertal group and nine in the pubertal group. All have subsequently had normal renal function tests, although during treatment eight children had plasma urea and creatinine concentrations transiently raised above age related normal values; three were from the prepubertal group and five from the pubertal group.

**Discussion**

Growth hormone excreted into the urine represents less than 0.002% of serum concen-
trations, and is the end product of renal metabolism including glomerular filtration, followed by extensive tubular reabsorption, and lysosomal hydrolysis. The rate limiting step under normal conditions is the filtration process as neither tubular reabsorption nor intracellular hydrolysis is saturated. Endogenous growth hormone production has been shown to increase in puberty by an amplitude modulated process. Furthermore, renal excretion of uGH increases in spontaneous puberty and after the treatment of delayed puberty with testosterone. Glomerular filtration rate, however, also increases in puberty, although changes in tubular function have not been described. Therefore our results showing a loss of the relationship between serum growth hormone and uGH during puberty are not totally unexpected in view of the changes in a number of important variables. The fact that our boys with CDGP showed a significant correlation between uGH excretion and serum growth hormone concentrations is interesting but not contradictory. Growth hormone concentrations in early puberty do not differ significantly from those in prepubertal boys and the majority of this group were in early puberty. Unfortunately the mean values shown in table 3 are not directly comparable as groups 1 and 2 had 24 hour profiles and urine collections in group 3 boys had 12 hour studies. The mean total concentrations in group 3 are likely to be higher than those of groups 1 and 2 as they do not include daytime growth hormone secretion when less growth hormone is produced.

Significant correlations between uGH excretion and both the growth hormone response to provocative tests and the mean serum growth hormone concentrations during profiles in diabetic and normal children, normal, short statured and growth hormone deficient children, and normal and short statured adults have been described. Okuna et al investigated prepubertal children only, and Weissberger et al studied adults, patients with acromegaly, and only 12 children, whose pubertal stage was not specified. Edge et al analysed changes in uGH excretion during puberty but did not state the pubertal status of the children undergoing growth hormone profiles. Therefore the significant correlation found in the latter group may reflect a majority of prepubertal and early pubertal children (age range 5-9-15-9 years).

In adults single overnight uGH measurements were found not to discriminate completely between those with acromegaly and normal controls, nor was there a significant correlation between uGH excretion and serum growth hormone concentrations in the adults with active acromegaly. This may be due to changes in renal function caused by growth hormone itself. In addition, within an individual, significant day to day variability in uGH excretion of the order of 30% has been described. The latter is most probably due to changes in renal function. The lack of any correlation between the dose of growth hormone administered and amount of uGH measured in the urine in growth hormone insufficient children provides further evidence for the individual variability of growth hormone handling. Furthermore, the excretion of uGH increases in renal failure and diabetic children regardless of changes in growth hormone secretion, but it is not significantly correlated with the excretion of other urinary proteins thereby underlining the importance of variations of renal function on uGH excretion. Although they have been at particular risk of incurring renal damage either as a result of their original disease or in the course of its treatment. Although there is no evidence of overt renal problems in the ALL children studied, they could have incurred sufficient tubular damage during treatment to affect renal handling of growth hormone. The fact that the prepubertal children with ALL were not significantly different from the normal prepubertal children in their excretion of uGH, however, argues against significant tubular damage affecting uGH excretion in these children. There was no difference in treatment, clinical course, or time elapsed since treatment between the prepubertal and pubertal irradiated children, although the children who were pubertal at the time of study were significantly older when originally treated than the prepubertal children (7-3 3-1 vs 3-8 2-1 years, p<0.05). If anything this would render them less vulnerable, as young children are more susceptible to permanent kidney damage from insults such as uGH injection. These observations counter the suggestion that tubular damage in group 1 disrupted uGH excretion. Furthermore the absence of a relationship between uGH excretion and serum concentrations in the normal pubertal group cannot be explained by renal pathology.

In conclusion, further investigation of the impact of both physiological and pathological changes in renal function on uGH excretion are necessary to determine the reliability of uGH as a screening test for growth hormone deficiency. Estimation of uGH does not appear to reflect serum growth hormone concentrations reliably in mid to late puberty and thus is not an appropriate screening test for growth hormone deficiency during puberty. Careful measurement of growth and the more traditional methods of growth hormone assessment remain essential.

Table 3 Relationship between mean serum growth hormone and total uGHng/g creatinine. Results are mean (SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>No of children</th>
<th>Mean serum growth hormone (IU/1)*</th>
<th>Total uGH (ng/g creatinine)</th>
<th>r</th>
<th>p  Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepubertal (24 hour profile):</td>
<td>Total 17</td>
<td>13·7 (7·6)</td>
<td>0·82</td>
<td>&lt;0·001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Normal 10</td>
<td>12·7 (5·3)</td>
<td>0·84</td>
<td>0·003</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALL 7</td>
<td>13·8 (10·5)</td>
<td>0·88</td>
<td>0·009</td>
<td></td>
</tr>
<tr>
<td>Prepubertal (24 hour profile):</td>
<td>Total 22</td>
<td>18·8 (6·9)</td>
<td>0·26</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Normal 8</td>
<td>17·0 (12·6)</td>
<td>0·02</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALL 14</td>
<td>19·7 (19·4)</td>
<td>0·40</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

*Conversion factor for growth hormone: 2 IU/1=1ng/L.

We are grateful for the support of the Leukaemia Research Fund and Eli Lilly during this study and to Mr D Ryder for statistical advice.


Relationship between urinary and serum growth hormone and pubertal status.

E C Crowne, W H Wallace, S M Shalet, G M Addison and D A Price

*Arch Dis Child* 1992 67: 91-95
doi: 10.1136/adc.67.1.91

Updated information and services can be found at:
http://adc.bmj.com/content/67/1/91

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/